Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701).

被引：3
|
作者：
LaPointe, Nichole
Hertle, Nick
Hsu, Shu Chi
Kellis, James
King, Nita
Littrell, Joshua
Quyen Nguyen
Ren, Jianan
Srdanov, Marko Romeo
Tanna, Vaishali
Thakrar, Sanchit
Zhao, Tianxun
Saiz, Robert
Le Bail, Nathalie
Bauchet, Anne-Laure
Lacoste-Bourgeacq, Anne-Sophie
Chadjaa, Mustapha
Ferrari, Paul
机构：
[1] Agilent, Carpinteria, CA USA
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Vitry Sur Seine, France
[4] Sanofi, Chilly Mazarin, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21030
引用
收藏
页数：3
相关论文
共 11 条
  • [1] Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
    Gazzah, A.
    Bedard, P. L.
    Hierro, C.
    Kang, Y-K
    Razak, A. Abdul
    Ryu, M-H
    Demers, B.
    Fagniez, N.
    Henry, C.
    Hospitel, M.
    Soria, J-C
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 416 - 425
  • [2] Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
    Decary, Stephanie
    Berne, Pierre-Francois
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Dabdoubi, Tarik
    Cameron, Beatrice
    Rival, Pierrick
    Devaud, Catherine
    Prades, Catherine
    Bouchard, Herve
    Casse, Alhassan
    Henry, Christophe
    Amara, Celine
    Brillac, Claire
    Ferrari, Paul
    Macon, Laetitia
    Lacoste, Eric
    Combeau, Cecile
    Beys, Eric
    Naimi, Souad
    Garcia-Echeverria, Carlos
    Mayaux, Jean-Francois
    Blanc, Veronique
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6589 - 6599
  • [3] Development of a novel antibody-drug conjugate targeting both CEACAM5 and CEACAM6
    Arias, K.
    Enos, C.
    Spear, M.
    Austin, D.
    Almofeez, R.
    Kortchak, S.
    Pincus, L.
    Kwon, Y.
    Gelber, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S87 - S87
  • [4] First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)
    Gazzah, A.
    Stjepanovic, N.
    Ryu, M. H.
    Tabernero, J.
    Soria, J. C.
    Bedard, P.
    Kang, Y. K.
    Bahleda, R.
    Guillemin-Paveau, H.
    Henry, C.
    Hatteville, L.
    Zilocchi, C.
    Demers, B.
    Hierro, C.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S14 - S15
  • [5] Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study
    Pouzin, Clemence
    Tod, Michel
    Chadjaa, Mustapha
    Fagniez, Nathalie
    Nguyen, Laurent
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (03): : 384 - 394
  • [6] Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) tumor expression in a phase I/II study of tusamitamab ravtansine (SAR408701) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Scoazec, J-Y.
    Bauchet, A-L.
    Adam, J.
    Rochaix, P.
    MacGrogan, G.
    Kim, J. E.
    Nuciforo, P.
    Lopez-Rios, F.
    Frisman, D.
    Cesarone, G.
    Bernstein, S.
    Lee, J.
    Henry, C.
    Ozoux, M-L.
    Lefebvre, A-M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
  • [7] Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
    Clemence Pouzin
    Leonid Gibiansky
    Nathalie Fagniez
    Mustapha Chadjaa
    Michel Tod
    Laurent Nguyen
    Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49 : 381 - 394
  • [8] Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Ricordel, Charles
    Barlesi, Fabrice
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Ghiringhelli, Francois
    Chadjaa, Mustapha
    Masson, Nina
    Soufflet, Christine
    Gazzah, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Gazzah, Anas
    Ricordel, Charles
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Chadjaa, Mustapha
    Hospitel, Marie
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
    Pouzin, Clemence
    Gibiansky, Leonid
    Fagniez, Nathalie
    Chadjaa, Mustapha
    Tod, Michel
    Nguyen, Laurent
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (03) : 381 - 394
12